Ceryx /ˈsiriks/ ubiquitous, trusted heralds acting as inviolable messengers.
Premaitha Licenses NIPT Tech From Illumina Under Settlement https://t.co/gDxn26MaDd
Congrats @Qiagen and @neumodx for the merger. Qiagen, NeuMoDx Ink Partnership, Merger Agreement https://t.co/R47dqyLOhe
An often overlooked trend in the diagnostics industry: the silent wave of sample-to-answer platform acquisitions. Read our take on this and let us know what you think. https://t.co/esf3VpEG5s
Sobering op-ed in the NYT. Us working in Precision Medicine must remain humble and keep working for patients. "Are We Being Misled About Precision Medicine?" https://t.co/1MpeoYYud9
Microarray for POC: Novacyt, Applied Microarrays Partner on SNP Assay Development https://t.co/V983LvNjph
Bristol-Myers Squibb to Use Natera's Cell-Free DNA Assay in Immunotherapy Study https://t.co/29d1y8IvEm
Great recommendations for any development team in biotech: understand your three categories of risk, how they distributed, and how to derisk by transforming beliefs into knowledge
Risk: A User’s Guide For Drug Developers https://t.co/xSNK1l99mk
Great example of how care is moving closer to the patient: NorthShore Betting on POC MDx Platform to Compete with Urgent Care Centers https://t.co/30MxOdiwBH
Another great example of efforts to deliver "sample to answer" workflow
Fluidigm, GenomOncology Partner to Create Integrated Workflow for Immuno-Oncology Research https://t.co/NckOTfFatP
Biocartis, Wondfo Announce Chinese Joint Venture https://t.co/lEyWmgT4BA
Biocartis Licenses EGFR Ectodomain Mutations https://t.co/TeRmS5g7ST
Roche's CEO of Diagnostics division bids adieu https://t.co/WmaoyxCcmS $RHHBY
New mRNA Cancer Drivers Revealed in Chronic Lymphocytic Leukemia https://t.co/yq9mwTkCRV
Illumina Receives Approval of MiSeq™Dx System in China - https://t.co/fc3YFPLJkQ
Good example of how to leverage a great commercial team to increase adoption of a great test. Congrats @exactsciences and @pfizer.
Exact Sciences, Pfizer to Comarket Cologuard https://t.co/ADVzk8x7kp
A test that tracks ctDNA levels can predict how patients with #DLBCL will respond to therapy within days of starting treatment https://t.co/1VCtXzBiO3 via @AJMC_Journal
@jajezmaz @EricTopol @DReuland @NPR @gordonmara1 And it will get more difficult to counsel as tests become more comprehensive. One example is molecular diagnostics, where panels are getting bigger. Patients sometimes think "more is better" but regret it once they get the results.
"It is incredibly exciting to study life’s blueprint during a time when it is within our grasp to understand what it really means." Great piece by @annewoj23 on what makes us human. The Codes That Bind Us, and Set Us Apart https://t.co/xkGlBOAFLN